It was great to join the Convenzis team again for the patient flow event. As always, the team were incredibly accommodating and happy to help. The quality of attendees is always of a high standard and relevant to the patient flow and to us also. We continue to have great discussions and footfall around our stand with no need to try and encourage people to come and see us. Really positive event for us and we look forward to working with Convenzis in the future.
Dr Heather Shaw
Consultant Medical Oncologist
University College London Hospital and Mount Vernon Cancer Centre
Heather Shaw, FRCP
Mount Vernon Cancer Centre, Northwood, UK and University College London Hospital, London, UK
Dr Heather Shaw is a Consultant Medical Oncologist at Mount Vernon Cancer Centre in Northwood and
lead for the Medical Oncology Skin Cancer Service at University College London Hospital, London. Dr
Shaw's main interests include the development of new strategies for the treatment of melanoma,
including rare subtypes such as ocular, and novel therapies to overcome resistance to currently available
treatments and maximise benefit for patients. She has an specialty interest in the management of
immunotherapy adverse events and is involved in development of local and national guidance while
leading services in both institutions for acute patient management.
Dr Shaw is the oncology representative on the Skin Cancer Prevention Group of the British Association of
Dermatologists, a member of the national Uveal Melanoma Surveillance Guideline Committee, The
Advanced Cellular Therapy Sub-Committee of British Society of Bone Marrow Transplantation and
Cellular Therapy and has provided governmental advisory input to the UK All Party Parliamentary Group
on Cancer with regard to cutaneous squamous cell carcinoma.
She is currently National Coordinating Investigator for a several international groundbreaking melanoma
studies including cellular and vaccine therapy indications which will deliver first in class licensed
indications, and Principal Investigator for a large portfolio of melanoma, cutaneous squamous cell
carcinoma, and early phase studies including first in human.
